Literature DB >> 9185753

Cardiac muscarinic receptor function in rats with cirrhotic cardiomyopathy.

D N Jaue1, Z Ma, S S Lee.   

Abstract

The pathogenesis of cirrhotic cardiomyopathy remains unclear. Because ventricular contractility is dependent on the interplay of stimulatory beta-adrenergic and inhibitory muscarinic receptors, we aimed to examine a possible role of muscarinic M2 receptor overactivity in a rat model of cirrhotic cardiomyopathy. Cirrhosis was induced by bile duct ligation (BDL), while controls underwent sham operations. Contractile responses to the muscarinic agonist carbachol were measured in situ in the autonomic-denervated pithed rat and in vitro in isolated ventricular papillary muscles. Ventricular sarcolemmal plasma membranes were isolated by sucrose density gradients, and muscarinic receptor characteristics were studied using 1-[N-methyl-3H]scopolamine (NMS). Membrane adenylyl cyclase activity was tested by a protein binding assay. Maximum first time derivative of peak ventricular systolic pressure (+dP/dt) for sham-operated and cirrhotic rats at baseline was 3,599 +/- 296 versus 1,226 +/- 63 mm Hg/sec (P < .01). Maximum first time derivative of ventricular diastolic relaxation (-dP/dt) for sham and cirrhotic rats at basal levels was -3,040 +/- 235 versus -864 +/- 59 (P < .01). The +dP/dt(max), and -dP/dt(max) responses to carbachol were blunted in the cirrhotic rats. The cirrhotic papillary muscles showed significantly less inhibition to incremental doses of carbachol than control rat muscles. Likewise, isoproterenol-stimulated membrane adenylyl cyclase activity was significantly less inhibited by carbachol doses in the cirrhotic rats. Membrane M2 receptor density and binding affinity in cirrhotic rat hearts were similar to controls. We conclude that muscarinic responsiveness was blunted in cirrhotic hearts, but this was not caused by receptor down-regulation, suggesting changes in postreceptor factors. These changes in muscarinic function are likely compensatory, and M2 receptor overactivity is not involved in the genesis of cirrhotic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185753     DOI: 10.1002/hep.510250610

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

Review 2.  Echocardiography in the Liver Transplant Patient.

Authors:  Parul Kakar; James Gubitosa; Christine Gerula
Journal:  Curr Cardiol Rep       Date:  2021-07-03       Impact factor: 2.931

Review 3.  Cirrhotic cardiomyopathy: a cardiologist's perspective.

Authors:  Natig Gassanov; Evren Caglayan; Nasser Semmo; Gero Massenkeil; Fikret Er
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  IgG from patients with liver diseases inhibit mitochondrial respiration in permeabilized oxidative muscle cells: impaired function of intracellular energetic units?

Authors:  Lumme Kadaja; Kai E Kisand; Nadezhda Peet; Urmo Braun; Kaja Metsküla; Kaupo Teesalu; Riina Vibo; Kalle V Kisand; Raivo Uibo; Harald Jockusch; Enn K Seppet
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

Review 5.  Cardiopulmonary complications in chronic liver disease.

Authors:  Soren Moller; Jens H Henriksen
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

6.  Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy.

Authors:  Seyed Soheil Saeedi Saravi; Mahmoud Ghazi-Khansari; Shahram Ejtemaei Mehr; Maliheh Nobakht; Seyyedeh Elaheh Mousavi; Ahmad Reza Dehpour
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

Review 7.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

Review 8.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

9.  Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis.

Authors:  Moon Young Kim; Soon Koo Baik; Chan Sik Won; Hong Jun Park; Hyo Keun Jeon; Hyun Il Hong; Jae Woo Kim; Hyun Soo Kim; Sang Ok Kwon; Jang Young Kim; Byung Su Yoo; Seung Hwan Lee
Journal:  Korean J Hepatol       Date:  2010-12

Review 10.  Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.

Authors:  Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2010 Jul-Sep       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.